NCT04182516 - Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

March 31, 2023

Study Completion Date

May 16, 2024

Conditions

Advanced/Metastatic Solid Tumors

Interventions

DRUG

NMS-03305293

All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.

Trial Locations (10)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan

Istituto Oncologico Veneto IRCCS, Padua

Centro Ricerche Cliniche di Verona Srl, Verona

MD Anderson Cancer Center, Houston

MHAT - Dobrich AD (Department of medical oncology), Dobrich

MHAT Sveta Sofia EOOD (Department of medical oncology), Sofia

MHAT Women's Health - Nadezhda OOD (Clinic of medical oncology), Sofia

Fudan University Shanghai Cancer Center, Shanghai

TianJin Medical University Cancer Institute & Hospital, Tianjin

University College London Hospitals NHS Foundation Trust, London